2025-08144RuleWallet

FDA Classifies Non-Bug Infection Spotter Device

Published Date: 5/9/2025

Rule

Summary

The FDA is officially putting devices that detect and measure non-microbial markers to find localized infections into a safer, more manageable category called Class II. This change, effective May 9, 2025, means these devices will face fewer regulatory hurdles, making it easier and faster for patients to get access to new, helpful infection-detecting tools. Companies making these devices will now follow special safety rules but avoid the toughest approval process, saving time and money.

Analyzed Economic Effects

4 provisions identified: 3 benefits, 1 costs, 0 mixed.

Faster patient access to new infection tests

FDA is classifying devices that detect and measure non-microbial markers to help find localized human infections as Class II (special controls), effective May 9, 2025 (classification applicable May 23, 2019). FDA says this classification will reduce regulatory burdens and enhance patients' access to beneficial innovative devices.

Manufacturers can use 510(k) pathway

Because FDA has classified this device type into Class II via De Novo, the device can serve as a predicate for future devices and sponsors can use the less-burdensome 510(k) premarket notification process instead of premarket approval. The order codifies the device type at 21 CFR 866.3230 and states the device is subject to premarket notification under section 510(k).

Mandatory labeling to prevent misinterpretation

Manufacturers must include specific labeling under 21 CFR 866.3230, such as a detailed intended use, performance characteristics, interpretation guidance, and limiting statements including that a negative test result does not preclude infection and that results should be interpreted with other clinical and laboratory data.

Required studies, validation, and training for makers

The special controls require manufacturers to provide detailed design descriptions, analytical performance documentation (e.g., limits of detection/quantitation), clinical study data comparing performance to an FDA-accepted reference or comparator, evaluation of analyte levels in asymptomatic patients, end-user training programs, risk mitigation strategies, and software impact descriptions as part of premarket submissions.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
5/9/2025
5/9/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register